Workflow
Pyridine Market Global Forecast Report 2025: A $1.07 Billion Industry by 2033 by High Demand from North America, Europe, and Asia-Pacific
GlobeNewswire· 2025-02-05 09:14
Pyridine Market Pyridine Market Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "Pyridine Market Global Forecast Report by Type, Application, End Use, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering.From US$ 706.14 million in 2024 to US$ 1.07 billion by 2033, the global pyridine market is expected to grow at a compound annual growth rate (CAGR) of 4.83% from 2025 to 2033 The growing need for pyridine in food additives, agrochemicals, and pharmaceutical ...
STRATEGIC EXPANSION INTO DATA CENTRE FACILITY BUSINESS AND GREEN ENERGY SECTOR, WITH PLANNED CAPITAL RAISE THROUGH ISSUANCE OF CONVERTIBLE LOAN NOTES
GlobeNewswire· 2025-02-05 09:14
HRC WORLD PLC NASDAQ FIRST NORTH, COPENHAGENTICKER: HRC:CPHISIN: GB00BZ3CDY20 5 February 2025 ANNOUNCEMENT OF STRATEGIC EXPANSION INTO DATA CENTRE FACILITY BUSINESS AND GREEN ENERGY SECTOR, WITH PLANNED CAPITAL RAISE THROUGH ISSUANCE OF CONVERTIBLE LOAN NOTES Copenhagen, 5 February 2025 – HRC World Plc (HRC:CPH), a Nasdaq First North Copenhagen-listed company, is pleased to announce its strategic expansion into the data centre facility business and planned involvement in the green energy sector in Malaysia, ...
Google pledge against using AI for weapons vanishes
Techxplore· 2025-02-05 09:11
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Google's original principles when it came to developing artificial intelligence were not to use it for weapons or surveillance that could infringe on people's rights. Google on Tuesday updated its principles when it comes to artificial intelligence, removing vows not to use the technology for weapons or surveillance. Revised A ...
F5, Inc.: Long-Term Growth Outlook Has Gotten Better Due To AI-Related Demand
Seeking Alpha· 2025-02-05 09:11
I recommended a buy rating for F5, Inc. (NASDAQ: FFIV ) when I wrote about it last October, as I expected it to achieve its FY25 guidance, driven by a better macro environment and an increase inI consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethical, and long- ...
1 Wall Street Analyst Thinks Apple Stock Is Going to $260. Is It a Buy?
The Motley Fool· 2025-02-05 09:11
Apple (AAPL 2.10%) is a stock that has frequently delivered for its shareholders and is set to continue doing so deeper into 2025. This is the view of one analyst tracking the stock who feels it's poised for a double-digit increase in price.His latest take on the company reflected a generally good fiscal fist quarter of 2025, the results of which were published at the end of January. For this pundit, the mighty tech titan still has plenty of prosperity in store -- and I agree.A bull stays the courseA day af ...
Meta Platforms: A Gem In The AI Bull Run
Seeking Alpha· 2025-02-05 09:10
Meta Holdings (NASDAQ: META ) (NEOE: META:CA ) entered the Q4 report with significant tailwinds on the back of an extremely resilient ad business and the booming AI trade. The company has several of the world's leading social mediaRetail investor researching mostly semiconductors and fintech. Some general macro musings. My goal is to bring you timely and digestible research on the stocks that I cover.Analyst’s Disclosure: I/we have a beneficial long position in the shares of META either through stock owners ...
Apple shares fall 3% in premarket after China reportedly considers probe into App Store practices
CNBC· 2025-02-05 09:08
An Apple Store in the Jiefangbei commercial district, adorned with a golden apple and snake motif to celebrate the Chinese Year of the Snake, on Jan. 14, 2025 in Chongqing, China.Apple shares fell on Wednesday after Bloomberg reported that Chinese regulators are considering whether to open a formal probe into the iPhone giant's App Store fees and policies.Shares of Apple were down 2.6% at 09:06 a.m. London time in premarket trading. The State Administration for Market Regulation (SAMR) is looking into polic ...
PagSeguro: A Perfect Buying Opportunity After The Recent Downtrend
Seeking Alpha· 2025-02-05 09:06
This is my first coverage of PagSeguro (NYSE: PAGS ). In the article, I will describe PagSeguro's business areas and my opinion on why I think after the recent pullback, the company is undervalued. I will go intoI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article means don't touch the stock; ...
Prediction: Palantir Will Beat the Market. Here's Why.
The Motley Fool· 2025-02-05 09:05
Palantir Technologies (PLTR 23.99%) already delivered explosive earnings and stock price performances to investors last year. The company's quarterly revenue soared in the double digits, profit reached records, and the stock jumped 340% for the best performance in the S&P 500 (^GSPC 0.72%).The company reached key milestones too, such as joining that major benchmark, as well as winning a spot in the Nasdaq-100.All of this is thanks to a solid software business built up over 20 years, and in recent times, the ...
Candidiasis Global Clinical Trials Review 2024: Top Countries, Trial Status, Trial Phase, Sponsor Type and End Point Status
GlobeNewswire· 2025-02-05 09:04
Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "Candidiasis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based ...